Glenmark Pharmaceuticals on Friday said it has received final approval from the USFDA for Pimecrolimus cream, used to treat skin conditions such as eczema. The approved product is a generic version of Elidel cream 1 per cent, of Bausch Health US, LLC. Citing IQVIA sales data, Glenmark said, Elidel cream achieved annual sales of approximately $198.8 million in the 12-month period ended July 2019. The company said its current portfolio consists of 160 products authorised for distribution in the US and 55 Abbreviated New Drug Applications (ANDA) pending approval with the USFDA. Shares of Glenmark Pharma closed at ₹383.90 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.